Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy

BJU International

Volumn 99, Issue 2, 2007, Pages 315-320

  Miyake, Hideaki ^a   Kurahashi, Toshifumi ^a   Hara, Isao ^a   Takenaka, Atsushi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Micrometastasis; Neoadjuvant hormonal therapy; Prostate cancer; Radical prostatectomy; Real time reverse transcriptase chain reaction

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADJUVANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; NEOADJUVANT THERAPY; PELVIC NEOPLASMS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33846244714     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06622.x     Document Type: Article

References (21)

1. Lee HH, Warde P, Jewett MA. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 1999; 83: 438-48
2. Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164: 1465-72
3. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9
4. Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol 2000; 163: 1183-8
5. Potter SR, Mangold LA, Shue MJ et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer 2000; 89: 2577-86
6. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001
7. Van Trappen PO, Gyselman VG, Lowe DG et al. Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet 2001; 357: 15-20
8. Inokuchi M, Ninomiya I, Tsugawa K, Terada I, Miwa K. Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br J Cancer 2003; 89: 1750-6
9. Ferrari AC, Stone NN, Kurek R et al. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006; 24: 3081-8
10. Miyake H, Hara I, Kurahashi T, Inoue T, Eto H, Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase polymerase chain reaction targeting prostate-specific antigen and prostate-specific membrane antigen genes. Clin Cancer Res 2006; in press
11. Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 2005; 11: 3773-7
12. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 2005; 96: 895-9
13. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-6
14. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160: 2428-34
15. Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer. results of an autopsy study and implications for the clinic. J Urol 1996; 156: 1969-71
16. Gleave M, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000; 56: 289-94
17. Miyake H, Sakai I, Harada K, Takechi Y, Hara I, Eto H. Prognostic significance of the tumor volume in radical prostatectomy specimens after neoadjuvant hormonal therapy. Urol Int 2005; 74: 27-31
18. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 849-54
19. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66-73
20. Shariat SF, Roudier MP, Wilcox GE et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph node. Cancer Res 2003; 63: 4662-70
21. Haas CJ, Wagner T, Wawroschek F, Arnholdt H. Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients. Pathol Res Pract 2005; 200: 763-70